

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Zhaoke Ophthalmology Limited
兆科眼科有限公司

(Incorporated in the British Virgin Islands with limited liability and continued in the Cayman Islands)
(Stock Code: 6622)

**VOLUNTARY ANNOUNCEMENT – REACHING EXCLUSIVE
DISTRIBUTION AGREEMENT TO COMMERCIALIZE TONO-i
IN GREATER CHINA FOR SELF-MEASUREMENT OF
INTRAOCULAR PRESSURE**

This announcement is made by the board of directors (the “**Board**”) of Zhaoke Ophthalmology Limited (the “**Company**”) on a voluntary basis.

The Board of the Company is pleased to announce that the Company has reached an exclusive distribution agreement on TONO-i with C&V Tech, a leading company in the development of medical devices for the diagnosis, treatment, and prevention of glaucoma. Under the terms of the agreement, the Company has exclusive rights to register, import, promote, distribute, market and sell TONO-i in Greater China.

TONO-i is an innovative tonometer designed to be contactless, portable, self-measuring, convenient and affordable. Unlike conventional contact-type tonometer, TONO-i is safe to use without the need for anaesthesia, pain nor the risk of contamination.

Self-measurement of intraocular pressure (“**IOP**”) is a paradigm shift in glaucoma management. TONO-i will become an integral part of the Company’s glaucoma franchise to address the unmet need of low diagnosis and treatment rates in China. It provides a tool for ophthalmologists to monitor patients’ IOP conveniently, accurately and thoroughly through self-measurement. It will likely improve patient compliance for glaucoma drug treatment by giving instant and continuous feedback on its efficacy. Inclusion of TONO-i in the Company’s pipeline signifies the Company’s commitment in glaucoma management in both treatment and diagnosis.

ABOUT GLAUCOMA

According to China Insights Consultancy, glaucoma, the second-leading cause of blindness worldwide, is a chronic and progressive disease associated with high IOP, resulting in optic nerve damage. The IOP is determined by the balance of the rate of fluid production versus fluid drainage in the eye. Substantially all the glaucoma cases are primary glaucoma, which can be generally classified into two types, open-angle glaucoma and angle-closure glaucoma. In China, approximately 40% of the primary glaucoma cases are open-angle glaucoma.

In China, the number of glaucoma patients grew from 13.4 million in 2015 to 15.3 million in 2019. Driven by the accelerating aging population, the number of glaucoma patients in China is expected to further grow to 20.0 million in 2030. In addition, the diagnosis rate of glaucoma is expected to increase significantly from 20.0% in 2019 to 60.6% in 2030.

ABOUT C&V TECH

C&V Tech was founded by Dr. Jin-Hui Kang at Wonju Medical Device Techno-Valley in South Korea in 2015. C&V Tech received major investments from Daewoo Pharmaceutical Co. (“**Daewoo Pharma**”) as a strategic partner, and Dr. Yong-Hoon Ji, an ophthalmologist from Seoul National University and now the CEO of Daewoo Pharma. Dr. Kang, with over 25 years’ experience in biotech research and entrepreneurship, including leading positions at Samsung Medical Center Life Science Research Institute, focused on the unmet needs in glaucoma patient care and invented a self-measurable tonometer, TONO-i. Daewoo Pharma, with its specialization in ophthalmology, has assisted in the development of TONO-i by C&V Tech, and is actively marketing this innovative product internationally.

By order of the Board
Zhaoke Ophthalmology Limited
Dr. Li Xiaoyi
Chairman

Hong Kong, November 8, 2022

As at the date of this announcement, the Board of the Company comprises Dr. Li Xiaoyi and Mr. Dai Xiangrong as executive Directors; Ms. Leelalertsuphakun Wanee, Ms. Tiantian Zhang, Ms. Cai Li and Mr. Chen Yu as non-executive Directors; and Mr. Wong Hin Wing, Prof. Lo Yuk Lam and Mr. Liew Fui Kiang as independent non-executive Directors.